Project Grant R15CA313615
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $467K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Waco, TX 76798, USA
Similar Awards
- The National Cancer Institute awarded the University of Texas at Arlington $565,569 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 1, 2026, for the design and synthesis of light-responsive osmium compounds to enable optical image-guided surgery and phototherapy in cancer treatment. The project will develop osmium compounds that luminesce at near-infrared wavelengths where tissue is most transparent, with the compounds engineered to be nontoxic to healthy tissue...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Baylor University $168,839 on July 17, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test geospatial artificial intelligence methods for sub-county cancer surveillance. The project applies neural cellular automata and graph neural networks to create geographic boundaries that improve cancer surveillance using individual-level cancer incidence data from the Texas...
- The National Cancer Institute awarded the University of Houston System $656,935 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop nanophotonic single exosome liquid biopsy technology for hepatocellular carcinoma screening and diagnosis. The project addresses limitations in current hepatocellular carcinoma surveillance methods, which rely on ultrasound and serum alfa-fetoprotein measurements that lack sensitivity and specificity for early...
- The National Cancer Institute awarded the University of Illinois $665,257 on September 3, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop molecular diagnostic methods for cervical cancer screening. The recipient will develop and validate a loop-mediated isothermal amplification (LAMP)-based assay for detecting high-risk human papillomavirus (HPV) infection in cervical samples, designed for point-of-care deployment in low-resource settings where access...
- The National Cancer Institute awarded The Leland Stanford Junior University $593,557 on March 18, 2026, under CFDA 93.394 (Cancer Detection and Diagnosis Research) to develop magnetic resonance methods for measuring response to an emerging lipophilic cancer therapy, specifically BPM31510, a coenzyme Q10 lipid nanoemulsion formulation. The research addresses a critical gap in clinical translation: the lack of real-time measurement tools to assess tumor response to this therapeutic agent, which...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Case Western Reserve University $630,108 on March 13, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The recipient will develop and evaluate theranostic approaches to breast cancer using a combined fluorescence image-guided surgery and photothermal therapy platform centered on AKRO-6QC, a molecule designed for specific binding and activation by cysteine proteases...
- The National Cancer Institute awarded Rutgers, The State University of New Jersey, School of Nursing $239,352 on August 11, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a sequencing-free PCR-based method for deep T-cell receptor profiling using sloppy molecular beacons in single-cell droplet digital PCR. The recipient will deliver a diagnostic technique that identifies T-cell receptor variable gene segment usage while preserving alpha-beta chain...
- The National Cancer Institute awarded New York University $703,227 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an ultra-rapid droplet digital PCR method for real-time molecular profiling of cancer-driving mutations during surgical resection. The funded work aims to engineer a microfluidic device that automates ultra-rapid DNA extraction and PCR thermal cycling to profile tissue samples in minutes rather than hours, enabling surgeons to...
- The National Cancer Institute awarded Yale University $607,690 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an MR-based platform for simultaneous intracellular pH (PHI) and extracellular pH (PHE) imaging in glioblastoma multiforme (GBM). The research aims to distinguish glycolytic and oxidative tumor phenotypes by measuring transmembrane pH gradients, which are larger in tumors than normal tissue and vary between metabolic phenotypes....
- The National Cancer Institute awarded the University of Washington $405,244 on August 13, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and optimize immunopixelseq, a cost-effective spatial immunosequencing platform for precision immuno-oncology research. Immunopixelseq uses 0.6-micrometer-resolution polony gel stamping to produce low-cost arrays compatible with standard Illumina short-read sequencing, enabling spatial co-profiling of whole-tissue...